Wells Fargo has initiated coverage on Centessa Pharmaceuticals PLC (CNTA) with an Overweight rating, marking the firm's first assessment of the biotechnology company. This rating reflects Wells Fargo's evaluation of Centessa's investment potential based on its research into the company's operations and the broader industry dynamics.
Centessa Pharmaceuticals, headquartered in Altrincham, Cheshire, is a clinical-stage pharmaceutical company focused on developing transformative medicines. The firm is currently advancing a new class of therapies within its orexin receptor 2 (OX2R) agonist program, targeting conditions such as excessive daytime sleepiness and various neuropsychiatric disorders. Additionally, Centessa is developing its LockBody technology platform within an early-stage immuno-oncology program.
As of September 2, 2025, Centessa's stock is priced at $28.04, with a market capitalisation of $3.8 billion. The company reported an earnings per share (EPS) of -1.82 for the trailing twelve months. Upcoming earnings are anticipated on August 10, 2026, with an EPS estimate of -0.43 and no revenue expected.
Analyst ratings serve as professional opinions derived from extensive research and financial modelling. While they may provide valuable insights, investors should consider a range of factors, including company fundamentals and market trends, before making decisions. Ratings can change as new information emerges, and different analysts may hold varying views on the same entity.